相关实验视频

Updated: Jan 13, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

[ATO和MET协同促进白血病细胞中亡的机制研究]

Meng Liu¹, Li-Wen-Hui Huang¹, Xiao-Hui Si²

¹School of Medical Technology, Xinxiang Medical University, Henan Key Laboratory of Immunology and Targeted Drugs, Henan Collaborative Innovation Center of Molecular Diagnosis and Laboratory Medicine, Xinxiang 453003, Henan Province, China.

Zhongguo shi yan xue ye xue za zhi

|January 8, 2026

概括

三氧化物 (ATO) 与甲胺 (MET) 结合,通过促进细胞亡,有效抑制白血病细胞的生长. 这种组合疗法对LKB1/AMPK通路进行上调,对PI3K/Akt通路进行下调,从而影响白血病细胞自.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

白血病仍然是一个重大的健康挑战,需要新的治疗策略.
三氧化物 (ATO) 和甲胺 (MET) 是具有潜在抗癌性能的已知药物.
了解白血病中ATO和MET的联合机制对于治疗开发至关重要.

研究的目的:

阐明三氧化 (ATO) 与甲胺 (MET) 结合的分子机制在白血病细胞中增强了亡.
研究这种联合治疗对细胞活力,细胞循环,细胞亡和关键信号通路的影响.

主要方法:

在KG1a,K562和THP1白血病细胞系中使用CCK-8试验评估细胞活力.
流细胞计被用来分析细胞周期分布和细胞亡率.
定量实时PCR (RT-qPCR) 和西区块被用于评估与PI3K/Akt和LKB1/AMPK通路相关的基因和蛋白质表达,以及自标志物 (LC3B,P62).

主要成果:

与单一治疗相比,ATO和MET的组合显著抑制了白血病细胞的生长,特别是在KG1a细胞系中.
结合治疗诱导了细胞循环停止,并促进了KG1a细胞的亡.
观察到LKB1/AMPK通路组件的上调和PI3K/Akt通路组件的下调,以及自标志物LC3B和P62.2的表达增加.

结论:

ATO与MET结合,可以协同促进白血病细胞的亡.
观察到的抗白血病效应是由LKB1/AMPK和PI3K/Akt信号通路的调节介导的.
这种组合疗法影响白血病细胞自,呈现出一个有前途的治疗途径.

关键词:

白血病;三氧化;甲胺;自;PI3K/Akt;AMPK

更多相关视频

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...